

# CURRICULUM VITAE – DR SONIA BOENDER

*Infectious disease epidemiologist & public health researcher, MSc PhD*

## PERSONAL INFORMATION

Full Name: Tamara Sonia Boender  
Email: [BoenderS@rki.de](mailto:BoenderS@rki.de)  
Website: <http://www.soniaboender.com>

## EDUCATION

2018 – 2020 (*expected*)

**MSc, Applied Epidemiology**

*Charité - Universitätsmedizin & Berlin School of Public Health, Berlin, Germany*

2013 – 2016

**PhD, Global Health**

*Faculty of Medicine, University of Amsterdam, the Netherlands*

Supervisors: Prof dr Tobias F Rinke de Wit & Prof dr Michael Boele van Hensbroek

Co-supervisors: Dr Kim CE Sigaloff & Dr Job CJ Calis

Thesis: Long-term effects of HIV treatment in sub-Saharan Africa: from access to quality (see full list of publications).

### Course work:

- UvA-AMC Graduate School: Systematic Reviews by the Cochrane Collaboration; BROK ICH-GCP; Advanced Topics in Biostatistics; Computing in R; Scientific Writing in English for Publication; DNA Technology.
- Erasmus Summer School NIHES 2014: Survival analysis ESP28.
- Virology Education: HIV Masterclass

2011 – 2012

**PGCert, International Public Health (*graduated with distinction*)**

*Liverpool School of Tropical Medicine, Liverpool, UK*

2010 – 2011

**MSc, Health Sciences - Public Health and Infectious Diseases**

*VU University Amsterdam, the Netherlands*

### Course Assistant (September 2010 – January 2011)

*Department of Health Sciences, VU University Amsterdam, Amsterdam, the Netherlands*

*Division Infectious Diseases, and Division Methodology and Applied Biostatistics*

PreMSc and BSc courses: epidemiology, research methodology (quantitative and qualitative), infectious diseases, public health and environment, introduction to health sciences.

### Research Internship (February – July 2011)

*PharmAccess Foundation, Amsterdam, the Netherlands*

Supervisors: Prof dr Tobias F Rinke de Wit

Co-supervisors: Dr Kim CE Sigaloff & Dr Job CJ Calis

Thesis: Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study.

(Published: Boender, *et. al*; AIDS Research and Treatment, 2012; see full list of publications)

2006 – 2010

**BSc, Health Sciences**

*VU University Amsterdam, the Netherlands*

Research Internship (October - December 2009)

*Center of Infectious Diseases, Department of Parasitology, Leiden Parasite Immunology Group, Leids Universitair Medisch Centrum, Leiden, the Netherlands*

Supervisors: Dr. Franca Hartgers & Dr. Maiza Campos Ponce

Thesis: Immune response to latent tuberculosis antigens modulated by helminth infection and living environment.

## **EMPLOYMENT**

September 2018 – today (*till September 2020*)

**Epidemiologist & Research Associate (ECDC EPIET Fellow)**

*Robert Koch Institute, Department of Infectious Disease Epidemiology, Surveillance Unit, Berlin, Germany*

September 2018 – today (*till September 2020*)

**ECDC EPIET Fellow**

*European Centre for Disease Prevention and Control (ECDC)*

European Programme for Intervention Epidemiology Training (EPIET) Fellowship.

Based at the German national public health institute, the Robert Koch Institute in Berlin, Germany.

ECDC Modules completed: EPIET Intro Course (Sept-Oct 2018), Outbreak Investigation (Dec 2018), Multivariable Analysis (March 2019), Rapid Assessment & Survey Methods (May 2019).

Visiting scientist

*Luxembourg Institute of Health (May 2019 – today)*

February 2016 – July 2018

**Epidemiologist & Postdoctoral Researcher**

*Stichting HIV Monitoring [Dutch HIV Monitoring Foundation], the Netherlands*

National HIV surveillance, monitoring of HIV treatment and quality of care; on behalf of the ATHENA national observational HIV cohort in the Netherlands.

Key responsibilities:

- Monitor the HIV epidemic and quality of care in the Netherlands, reported in the annual HIV Monitoring Report. Lead author of chapter 'Response to antiretroviral therapy', co-author on chapter 'Quality of care'; see full list of publications and presentations.
- Conduct clinical epidemiological and methodological research on the HIV epidemic. Publish findings in peer-reviewed scientific journals and present at national and international conferences; see full list of publications and presentations.
- Participate in international research collaborations:
  - o International Cohort Consortium of Infectious Diseases (RESPOND) Participant and member of the Scientific Interest Group 'Outcomes with antiretroviral drugs'.
  - o HIV-CAUSAL (HIV Cohorts Analyzed Using Structural Approaches to Longitudinal data) Participant of the Drug Resistance Working Group.

- Provide methodological advice and data analysis support for research proposals submitted by HIV treatment centres.
- Advise and support data management and data monitoring in the improvement of data collection protocols, standardisation of data processing, and data quality control.
- Student supervision (MSc and PhD level).

February 2012 – January 2016

**PhD Fellow**

*Amsterdam Institute for Global Health and Development & Emma Children's Hospital Global Child Health Group; Department of Global Health, Academic Medical Center of the University of Amsterdam, the Netherlands*

Surveillance and monitoring of outcomes of HIV treatment in adults and children in sub-Saharan Africa, including pre-treatment and acquired HIV drug resistance.

Key responsibilities:

- Project management of two multi-country HIV cohort studies in sub-Saharan Africa (Nigeria, Uganda, Kenya, Zimbabwe, Zambia, South Africa): the PASER (Pan-African Studies to Evaluate Resistance) and MARCH (Monitoring Antiretroviral Resistance in Children) cohorts.
- Conduct public health epidemiology studies; see full list of publications and presentations.

Expert consultant for the World Health Organisation - (WHO) HIVResNet

HIVResNet is a global network advising WHO on the control and surveillance of HIV drug resistance.

Key contributions:

- Conducted the WHO commissioned literature review and meta-analysis on long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries (Published: Boender et. al; Clin Infect Dis. 2015 Nov 1;61(9):1453-61).
- Contributed to the development of the 'Global Action Plan on HIV Drug Resistance, 2017-2021' and the 'HIV Drug Resistance Report 2017'.

April 2012 – February 2013

**Junior lecturer**

*Division Infectious Diseases, and Division of Methodology and Applied Biostatistics; Department of Health Sciences, VU University Amsterdam, the Netherlands*

Key responsibilities:

- Provide lectures and tutorials: Pre-MSc and BSc courses: epidemiology, research methodology (quantitative and qualitative), infectious diseases, public health and environment, introduction to health sciences.
- Supervise internal and external research internships.
- Support, plan and organise lectures and tutorials.
- Manage and train course assistants.

## ADDITIONAL ACTIVITIES & VOLUNTEER WORK

Since December 2018

### **satRday Berlin co-organiser**

satRday Berlin is a conference dedicated to the R programming language, and adheres to an open and open source philosophy, requiring it to be community based, volunteer run, affordable and to have diverse speakers and attendees.

The inaugural satRday Berlin took place on Saturday 15<sup>th</sup> June 2019.

<https://berlin2019.satrdays.org/>

Since September 2018

### **ECDC EPIET Cohort Representative** of cohort 2018 (elected)

Responsibilities: spokesperson and point of contact for fellows, the ECDC Fellowship programme heads, the training site forum, and the EPIET Alumni Network (EAN).

In collaboration with EAN: co-organiser of the ESCAIDE 2019 Career Compass; co-organiser of the EAN mini-module on Social Media for Public Health Professionals.

Since 2018

**Abstract reviewer** for International AIDS Society Conferences: International AIDS Conference (AIDS 2018) and IAS Conference on HIV Science (IAS 2019).

Since 2016

**Advisory board member** for the MSc and BSc Health Sciences, VU University Amsterdam, the Netherlands

Since 2015

**Peer-review** for The Lancet, the Journal of the International AIDS Society, PlosOne, BMJ Open, African Journal of Laboratory Medicine, AIDS Research and Human Retroviruses.

For a full list, see my reviewer profile at Publons: <http://publons.com/a/1225943/>

Since 2013

**Guest/invited lecturer** in infectious disease epidemiology, epidemiology of HIV and drug resistance:

- Healthcare Management and Modelling, 2<sup>nd</sup>/3<sup>rd</sup> year BSc Industrial Engineering Eindhoven University of Technology.
- Introduction to Health Sciences, 1<sup>st</sup> year BSc Health Sciences, VU University Amsterdam, the Netherlands.

Since 2012

**Student supervisor** Daily supervision of students in Health Sciences, Medicine, and Global Health on BSc, MSc and PhD level (>10 students).

2009 - 2010

**Peer-educator reproductive health** SCORA - Het Voorspel, the Netherlands.

2008 - 2009

**Board Secretary** The Dutch Red Cross Students Desk of Amsterdam, the Netherlands.

## PROFESSIONAL SKILLS & QUALIFICATIONS

### Computer skills

- Proficient in STATA, SAS, SPSS, Adobe Pro, GraphPad Prism, MS Office suite.
- Experience with R, EpiInfo, Nvivo, MS Access, QGIS/ArcGIS, Adobe Creative Suite (Photoshop, InDesign, Illustrator).

### Languages

- English: full professional proficiency (C2)
- German: working proficiency (B2/C1)
- Dutch: native speaker, full professional proficiency (C2)

### Certificates

- Registered Senior Epidemiologist, PhD level at the Dutch Society for Epidemiology (*Epidemioloog B, Vereniging voor Epidemiologie*) as of 15-06-2018.
- ICH Good clinical practice (GCP) certified, exam: 23-04-2013; re-certified: 20-03-2017, valid till 20-03-2021
- WHO GOARN eCourses: 'The Global Outbreak Alert and Response Network (GOARN)' and 'Working with GOARN in the field' both completed 12-05-2019.
- United Nations Department of Safety and Security (UNDSS) 'BSAFE course' completed 07-05-2019.
- OpenWHO training: 'Introduction: Operational Readiness (Tier 1)' completed 29-01-2019;

### Professional memberships

- Member of the EPIET Alumni Network (EAN).
- Member of the Dutch Society for Epidemiology and International Epidemiological Association, and International Epidemiological Association (IEA).
- Member of the European AIDS Clinical Society (EACS).

### Other

- Drivers licence category B

# PUBLICATIONS & PRESENTATIONS

## Research papers

### Published

1. Compliance with laboratory monitoring guidelines in outpatient HIV care: a qualitative study in the Netherlands.  
Toxopeus DCM, Pell CL, Westrhenen NB, Smit C, Wit FWNM, Ondoa P, Reiss P, **Boender TS**.  
AIDS Care. 2019 Jan 2;1-8. doi: 10.1080/09540121.2018.1563280.
2. Previous antiretroviral drug use compromises standard first-line therapy in Africa and is mediated through drug-resistance.  
Inzaule SC, Kityo CM, Siwale M, Akanmu AS, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, **Boender TS**, Ondoa P, Sigaloff KCE, Rinke de Wit TF, Hamers RL.  
Scientific Reports. In press 2018. doi:10.1038/s41598-018-33538-0
3. AIDS Therapy Evaluation in the Netherlands (ATHENA) national observational HIV cohort: cohort profile.  
**Boender TS**, Smit C, Sighem AV, Bezemer D, Ester CJ, Zaheri S, Wit FWNM, Reiss P;  
ATHENA national observational HIV cohort.  
BMJ Open. 2018 Sep 24;8(9):e022516. doi: 10.1136/bmjopen-2018-022516.
4. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. Kroeze S, Ondoa P, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, **Boender TS**, de Punder ME, Sigaloff KCE, Reiss P, Wit FWNM, Rinke de Wit TF, Hamers RL. AIDS. 2018 May 15;32(8):1043-1051. doi: 10.1097/QAD.0000000000001801.  
Clin Infect Dis. 2018 Apr 17;66(9):1352-1359. doi: 10.1093/cid/cix1004.
5. Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.  
Lodi S, Günthard HF, Dunn D, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Schneider MP, Egger M, Glass TR, Reiss P, van Sighem A, **Boender TS**, Phillips AN, Porter K, Hawkins D, Moreno S, Monge S, Paraskevis D, Simeon M, Vourli G, Sabin C, Hernán MA; **HIV-CAUSAL Collaboration**.  
AIDS. 2018 Jan 28;32(3):327-335. doi: 10.1097/QAD.0000000000001692.
6. Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children.  
Kityo C\* & Boerma RS\*, Sigaloff KCE, Kaudha E, Calis JCJ, Musiime V, Balinda S, Nakanjako R, **Boender TS**, Mugenyi PN, Rinke de Wit TF. [*Authors contributed equally to the work*].  
J Antimicrob Chemother. 2017 Sep 1;72(9):2587-2595. doi: 10.1093/jac/dkx188.
7. [Twenty years of combination antiretroviral therapy for HIV infection in the Netherlands: progression and new challenges]. [Article in Dutch]  
Twintig jaar hiv combinatietherapie in Nederland.  
Brinkman K\* & **Boender TS\***, van der Valk M, van Sighem A, Reiss P, Kroon FP, namens het ATHENA observationele HIV cohort. [*Authors contributed equally to the work*]  
Ned Tijdschr Geneeskd. 2017;161(0):D1123.
8. Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts.  
Bijker R, Jiamsakul A, Kityo C, Kiertiburanakul S, Siwale M, Phanuphak P, Akanmu S, Chaiwarith R, Wit FW, Sim BL, **Boender TS**, Ditangco R, Rinke De Wit TF, Sohn AH, Hamers RL.  
J Int AIDS Soc. 2017 Mar 3;20(1):1-10. doi: 10.7448/IAS.20.1.21218.
9. High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children  
Boerma RS\* & **Boender TS\***, Sigaloff KCE; Rinke de Wit TF; Boele van Hensbroek M; Ndembu N; Adeyemo T; Temiye EO; Osibogun A; Ondoa, P, Calis JC\* & Akanmu AS\* [*Both*

- first and both senior authors contributed equally to the work].*  
J Int AIDS Soc. 2016 Nov 10;19(1):21140. doi: 10.7448/IAS.19.1.21140.
10. Suboptimal viral suppression rates among HIV-infected children in low- and middle-income countries: a meta-analysis.  
Boerma RS, **Boender TS**, Bussink AP, Calis JC, Bertagnolio S, Rinke de Wit TF, Boele van Hensbroek M, Sigaloff KC.  
Clin Infect Dis. 2016 Dec 15;63(12):1645-1654. doi: 10.1093/cid/ciw645
  11. Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.  
Boerma RS & Kityo C, **Boender TS**, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KC & Calis JC. [*Both first and both senior authors contributed equally to the work*].  
J Trop Pediatr. 2017 Apr 1;63(2):135-143. doi: 10.1093/tropej/fmw062.
  12. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.  
**Boender TS**, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, Labib Maksimos EE, Balinda SN, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Stevens W, Rinke de Wit TF, Sigaloff KC.  
J Infect Dis. 2016 Sep 15;214(6):873-83. doi: 10.1093/infdis/jiw219. Epub 2016 Jul 11.
  13. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.  
**Boender TS**, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, Siwale M, Nankya I, Kaudha E, Akanmu AS, Botes ME, Steegen K, Calis JC, Rinke de Wit TF, Sigaloff KC.  
J Antimicrob Chemother. 2016 Oct;71(10):2918-27. doi: 10.1093/jac/dkw218.
  14. HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda.  
Kityo C, Sigaloff KC, **Boender TS**, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde-Katumba L, Calis JC, Rinke de Wit TF, Mugenyi PN.  
AIDS Res Hum Retroviruses. 2016 Jul;32(7):628-35. doi: 10.1089/AID.2015.0215.
  15. Sequencing paediatric antiretroviral therapy in the context of a public health approach.  
Boerma RS, **Boender TS**, van Hensbroek MB, Rinke de Wit TF, Sigaloff KC.  
J Int AIDS Soc. 2015 Dec 2;18(Suppl 6):20265. doi: 10.7448/IAS.18.7.20265.
  16. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.  
**Boender TS**, Hoenderboom BM, Sigaloff KC, Hamers RL, Wellington M, Shamu T, Siwale M, Labib Maksimos EE, Nankya I, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Ondoa P, Rinke de Wit TF.  
Clin Infect Dis. 2015 Dec 1;61(11):1749-58. doi: 10.1093/cid/civ656.
  17. Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.  
**Boender TS**, Sigaloff KC, McMahon JH, Kiertiburanakul S, Jordan MR, Barcarolo J, Ford N, Rinke de Wit TF, Bertagnolio S.  
Clin Infect Dis. 2015 Nov 1;61(9):1453-61. doi: 10.1093/cid/civ556.
  18. Research in action: from AIDS to global health to impact. A symposium in recognition of the scientific contributions of Professor Joep Lange.  
**Boender TS**, Barré-Sinoussi F, Cooper D, Goosby E, Hankins C, Heidenrijk M, de Jong M, Kazatchkine M, Laoye F, Merson M, Reiss P, Rinke de Wit TF, Rogo K, Schellekens O, Schultsz C, Sigaloff KC, Simon J, Zewdie D.  
Antivir Ther. 2015;20(1):101-8. doi: 10.3851/IMP2946.
  19. Performance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe.  
Ondoa P, Shamu T, Bronze M, Wellington M, **Boender TS**, Manting C, Steegen K, Luethy R, Rinke de Wit T.  
Biomed Res Int. 2014;2014:102598. doi: 10.1155/2014/102598.
  20. Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study.  
**Boender TS**, Sigaloff KC, Kayiwa J, Musiime V, Calis JC, Hamers RL, Nakatudde LK, Khauda

E, Mukuye A, Ditai J, Geelen SP, Mugenyi P, Rinke de Wit TF, Kityo C.  
AIDS Res Treat. 2012;2012:817506. doi: 10.1155/2012/817506.

#### *Collaboration papers*

21. First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda.  
Poon AFY, Ndashimye E, Avino M, Gibson R, Kityo C, Kyeyune F, Nankya I, Quiñones-Mateu ME, Arts EJ; **The Ugandan Drug Resistance Study Team**.  
AIDS Res Ther. 2019 Jan 22;16(1):3. doi: 10.1186/s12981-019-0218-2.
22. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.  
Inzaule SC, Hamers RL, Noguera-Julian M, Casadellà M, Parera M, Kityo C, Steegen K, Naniche D, Clotet B, Rinke de Wit TF, Paredes R; **PanAfrican Studies to Evaluate Resistance**.  
2018 Nov;5(11):e638-e646. doi: 10.1016/S2352-3018(18)30177-2. Epub 2018 Sep 30.
23. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.  
Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; **Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group**.  
J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083.
24. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.  
Smolders EJ, Smit C, de Kanter C, Dofferhoff A, Arends JE, Brinkman K, Rijnders B, van der Valk M, Reiss P, Burger DM; **ATHENA National HIV Observational Cohort**.  
HIV Med. 2018 Mar;19(3):216-226. doi: 10.1111/hiv.12570. Epub 2017 Dec 1.
25. High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands.  
Boerekamps A, Newsum AM, Smit C, Arends JE, Richter C, Reiss P, Rijnders BJA, Brinkman K, van der Valk M; **NVHB-SHM Hepatitis Working Group and the Netherlands ATHENA HIV Observational Cohort**.  
Clin Infect Dis. 2018 Apr 17;66(9):1352-1359. doi: 10.1093/cid/cix1004.

#### *Preprints/Submitted*

- I. Acute hepatitis C infection among HIV-positive adults in the Netherlands: a capture-recapture analysis.  
**Boender TS**, Op De Coul E, Arends J, Prins M, van der Valk M, van der Meer J, van Benthem B, Reiss P Smit C.  
medRxiv 19002097; doi: <https://doi.org/10.1101/19002097>
- II. Effectiveness of transmitted drug resistance testing before initiation of antiretroviral therapy in HIV-positive individuals.  
Lodi S, Günthard HF, Gill J, Phillips AN, Dunn D, Vu Q, Siemieniuk R, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AN, Reiss P, van Sighem A, **Boender TS**, Porter K, Gilson R, Paraskevis D, Simeon M, Vourli G, Moreno S, del Amo J, Sabin C, Hernán MA; **The HIV-CAUSAL Collaboration**.
- III. Patient characteristics rather than choice for dolutegravir or elvitegravir determine the likelihood of cART discontinuation; evidence from the ATHENA national observational HIV cohort study in the Netherlands  
Bollen PDJ, Hakkers CS, **Boender TS**, van Crevel R, Brouwer A, Hoepelman IM, Reiss P, Wit FWNM, Arends JE, Burger DM, on behalf of the ATHENA national observational HIV cohort



## Other publications

1. Robert Koch-Institut: Infektions-epidemiologisches Jahrbuch für 2018, Berlin, 2019, 6.30 Kryptosporidiose; p. 151-154.
2. Monitoring Report 2018. Human Immunodeficiency Virus (HIV) Infection in the Netherlands. van Sighem A.I., **Boender T.S.**, Wit F.W.N.M., Smit C., Matser A., Reiss P. Amsterdam: Stichting HIV Monitoring, 2018.
  - Chapter 2: Response to combination antiretroviral therapy.  
**Sonia Boender**, Ard van Sighem, Ferdinand Wit, Kees Brinkman, Kees van Nieuwkoop, Anne Wensing, Peter Reiss
3. Monitoring Report 2017. Human Immunodeficiency Virus (HIV) Infection in the Netherlands. van Sighem A.I., **Boender T.S.**, Wit F.W.N.M., Smit C., Matser A., Reiss P. Amsterdam: Stichting HIV Monitoring, 2017. Available online at <http://www.hiv-monitoring.nl>
  - Chapter 2: Response to combination antiretroviral therapy.  
**Sonia Boender**, Ard van Sighem, Ferdinand Wit, Kees Brinkman, Kees van Nieuwkoop, Anne Wensing, Peter Reiss
  - Chapter 7: Quality of care.  
Colette Smit, Jan Prins, Kees Brinkman, Suzanne Geerlings, Frank Kroon, **Sonia Boender**, Peter Reiss.
4. Monitoring Report 2016. Human Immunodeficiency Virus (HIV) Infection in the Netherlands. van Sighem A.I., **Boender T.S.**, Wit F.W.N.M., Smit C., Matser A., Reiss P. Amsterdam: Stichting HIV Monitoring, 2016. Available online at <http://www.hiv-monitoring.nl>
  - Chapter 2: Response to combination antiretroviral therapy.  
**Sonia Boender**, Ard van Sighem, Ferdinand Wit, Kees Brinkman, Jan Prins, Anne Wensing, Peter Reiss
  - Chapter 7: Quality of care.  
Colette Smit, Jan Prins, Kees Brinkman, Suzanne Geerlings, Frank Kroon, **Sonia Boender**, Peter Reiss
5. PhD thesis: Long-term effects of HIV treatment in sub-Saharan Africa: from access to quality. **T.S. Boender**.  
Supervisors: Prof. dr. T.F. Rinke de Wit & Prof. dr. M. Boele van Hensbroek.  
Co-supervisors: Dr. K.C.E. Sigaloff & Dr. J.C.J. Calis.  
Date of PhD defense: May 20th, 2016.  
Available online at <http://hdl.handle.net/11245/1.530341>

## Conference proceedings

### Oral presentations

- Notification and registration of acute hepatitis C infection among HIV-positive adults [Presentation in Dutch: *Acute hepatitis C bij mensen met hiv: melding & registratie*], Annual SOA/HIV Expertmeeting, 22 June 2018, Netherlands National Institute for Public Health and Environment [Rijksinstituut voor Volksgezondheid en Milieu, RIVM], Bilthoven, the Netherlands.
- Accumulation of HIV-1 drug resistance after continued virological failure on first-line antiretroviral therapy in adults and children. Abstract #7.  
10<sup>th</sup> International Workshop on HIV Treatment, Pathogenesis, and Prevention Research in Resource Limited Settings (INTEREST), May 3-6 2016, Yaoundé, Cameroon.
- Protease Inhibitor Resistance at 2nd-Line HIV Treatment Failure in Sub-Saharan Africa. XXV International HIV Drug Resistance Workshop, 21-22 February 2016, Boston: Abstract #38.  
*Featured in:* Global Antiviral Journal Volume 12 Supplement 1.

- Pretreatment HIV Drug Resistance Increases Regimen Switch in Sub-Saharan Africa. Conference on Retroviruses and Opportunistic Infections (CROI) 23-26 February 2015, Seattle: Abstract #118.  
*Featured in:* Olender, S.A. et al., 2015. CROI 2015: Advances in antiretroviral therapy. *Top Antivir Med*, 23(1), pp.28–45.
- Pretreatment HIV Drug Resistance Increases Regimen Switch in Sub-Saharan Africa. XXIV International HIV Drug Resistance Workshop, 21-22 February 2015, Seattle: Abstract #3.  
*Featured in:* Prevalence of transmitted drug resistance globally: highest in Australia, US and some European countries but between-country differences in all regions. *iBase HIV Treatment Bulletin*. 24 March 2015.
- Continued virological failure and unnecessary switching of antiretroviral treatment for HIV-1 may occur despite access to viral load monitoring. African Society for Laboratory Medicine (ASLM) Conference 1 December 2014, Cape Town, South Africa.

#### *Poster presentations*

- Substantial decline in virological failure after combination antiretroviral treatment (cART) initiation in treatment-naïve HIV-positive adults in the Netherlands from 1996 to 2016. 22<sup>nd</sup> International AIDS Conference (AIDS 2018), Amsterdam, Netherlands, 23-27 July 2018. Abstract 1405.
- Acute hepatitis C infection among HIV-positive adults in the Netherlands: a capture-recapture analysis of two national databases. 22<sup>nd</sup> International Workshop on HIV and Hepatitis Observational Databases (IWHOD), Fuengirola, Spain, 22-24 March 2018. Abstract 036.
- Substantial decline in virological failure after combination antiretroviral treatment (cART) initiation in treatment-naïve HIV-positive adults in the Netherlands from 1996 to 2016. 22<sup>nd</sup> International Workshop on HIV and Hepatitis Observational Databases (IWHOD), Fuengirola, Spain, 22-24 March 2018. Abstract 115.
- Initiation of cART: a nationwide overview of variation between HIV treatment centres in the Netherlands. 9<sup>th</sup> IAS Conference on HIV Science (IAS), Paris, France, 23-26 July 2017. Abstract #WEPED1415.
- Durability of first-line combination antiretroviral therapy (cART) for HIV in the Netherlands. 21<sup>st</sup> International Workshop on HIV and Hepatitis Observational Databases (IWHOD), Lisbon, Portugal, 30<sup>th</sup> March - 1<sup>st</sup> April 2017. Abstract #110.
- HIV drug resistance after continued virological failure on first line antiretroviral therapy predicts limited role for second-generation non-nucleoside reverse transcriptase inhibitors in sub-Saharan Africa. 20<sup>th</sup> International Workshop on HIV Observational Databases (IWHOD) 7-9th April 2016, Budapest, Hungary. Abstract #123.
- Protease Inhibitor Resistance at 2nd-line HIV Treatment Failure in Sub-Saharan Africa. Conference on Retroviruses and Opportunistic Infections (CROI) February 22–25 2016, Boston, MA, USA. Abstract #498.  
*Featured in:* Taylor BS, Olender SA, Tieu HV, Wilkin TJ. CROI 2016: Advances in antiretroviral therapy. *Top Antivir Med* 2016 May-Jun;24(1):59-81.
- Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis. Netherlands Conference on HIV Pathogenesis, Epidemiology, Prevention and Treatment (NCHIV) 18 November 2014: Abstract #38.
- Favorable Long-term Outcomes of 2nd-line ART Despite Drug-Resistant HIV-1 in Sub-Saharan Africa. Conference on Retroviruses and Opportunistic Infections (CROI) 3-6 March 2014: Abstract #570.  
*Featured in:* Taylor BS, Shalev N, Wilkin TJ. CROI 2014: Advances in antiretroviral therapy. *Top Antivir Med* 2014 May; 22: 616–31.

## **Invited talks**

### *Science communication*

- HIV Next Gen Workshop, to mobilize 120 passionate students to become the next generation of HIV leaders and change makers (parallel to the AIDS 2018 conference), 23 July 2018.  
Session 4: How to limit the spread of the virus.  
Presentation and interview, together with Dr Stefano Vella.

### *Policy meetings*

- National Uganda Virus Research Institute Stakeholders' Workshop. Kampala, Uganda. March 11-12<sup>th</sup>, 2015. Workshop theme: Working together for better HIV laboratory services and improved delivery of prevention and care. Presentation: HIV Drug Resistance in Sub-Saharan Africa response to 1st-line ART.  
*Featured in newspaper article: New Vision, HIV drug resistance worries experts, March 13, 2015.*
- HIV Drug Resistance Technical Working Group, Harare, Zimbabwe. October 29<sup>th</sup>, 2015.  
Presentation title: Long-term HIV treatment outcomes: findings from the PASER study, highlights from Zimbabwe.